WO2022152289A1 - Anticorps modifié et conjugués anticorps-médicament le comprenant - Google Patents

Anticorps modifié et conjugués anticorps-médicament le comprenant Download PDF

Info

Publication number
WO2022152289A1
WO2022152289A1 PCT/CN2022/072296 CN2022072296W WO2022152289A1 WO 2022152289 A1 WO2022152289 A1 WO 2022152289A1 CN 2022072296 W CN2022072296 W CN 2022072296W WO 2022152289 A1 WO2022152289 A1 WO 2022152289A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
domain
drug
sequence
Prior art date
Application number
PCT/CN2022/072296
Other languages
English (en)
Inventor
Mingzhi JIN
Xiaoyue CHEN
Manrong LI
Lai JIANG
Li Yin
Jiexing CAI
Jun Wang
Original Assignee
Wuxi Biologics (Shanghai) Co., Ltd.
WuXi Biologics Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics (Shanghai) Co., Ltd., WuXi Biologics Ireland Limited filed Critical Wuxi Biologics (Shanghai) Co., Ltd.
Priority to CN202280010258.2A priority Critical patent/CN117255808B/zh
Priority to CN202410359231.5A priority patent/CN118221804A/zh
Publication of WO2022152289A1 publication Critical patent/WO2022152289A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Definitions

  • the present invention relates generally to the field of bio-pharmaceutical, and more particularly, engineered antibodies and antibody-drug conjugates.
  • Antibodies are multifunctional immunoglobulins carrying unique binding specificity for a target antigen and a series of antigen-independent immunological interactions, which allow them to play critical roles in the immune system.
  • Many currently used biological therapeutics, diagnosis and research agent are antibodies directed against antigens that are involved in the pathological, immunological or biological mechanism of interest.
  • ADC antibody-drug conjugate
  • ADC is comprised by an antibody for targeting, a linker for drug attachment and a high potent payload as an effector.
  • Antibody or its relevant forms brings the cytotoxic drugs to antigen-expressing cells or other target cells by antibody-antigen interaction.
  • MED Minimum Effect Dose
  • MTD Maximum Tolerance Dose
  • Mylotarg, Adcetris, Kadcyla, Besponsa, Polivy, Padcev, Enhertu, Trodelvy and Blenrep are examples of ADC drugs approved by FDA.
  • a successful ADC development depends on antibody selection, linker-payload selection, manner of linker-payload conjugation and conjugation process development.
  • Cysteine thiols in antibody as strong nucleophiles are ideal reaction groups for conjugation. Since cysteine residues exist as disulfide bonds in native form of antibodies, reduction of disulfide bonds between light-heavy chain and heavy-heavy chain in antibody provides perfect free cysteine thiols for conjugation.
  • Numerous conjugation methods have been developed in the art to address the opportunities and challenges afforded by having the preferred payload-antibody ratio (PAR) and conjugation positions. Ideally, moderate number of payloads should be attached to one antibody, resulting in heterogeneous ADC product.
  • PAR payload-antibody ratio
  • Thiomab TM technology was developed by Genentech with inducing cysteine mutation on antibody (Jagath R Junutula, et al., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index, Nature Biotechnology, 2008, 26 (8) : 925–932) .
  • Conjugation with Thiomab happened at the engineered cysteine residue after reduction, resulting in high homogeneous conjugate product.
  • Non-natural amino acid (NNAA) technology was also used for homogeneous conjugate production. For instance, keto group or azido moiety were induced to antibody by unnatural amino acid as conjugation site (Jun Y.
  • Site mutation-based method has several disadvantages. First of all, mutation site needs to be carefully selected, otherwise both antibody’s stability and conjugation efficiency will be affected. Secondly, expression level of the antibody with site mutation is usually very low, which may be a problem in the Chemistry, Manufacturing and Controls (CMC) stage.
  • CMC Chemistry, Manufacturing and Controls
  • LQG glutamine tag
  • mTG recognition motif Pavel Strop, et al., Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates, Chemistry &Biology, 2013, 20 (2) : 161-167)
  • LPETG sortase A recognition motif
  • Beerli et al., Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency, PLOS ONE, 2015, 10 (7) : e0131177)
  • LCxPxR as formylglycine-generating enzyme (FGE) recogniztion motif
  • FGE formylglycine-generating enzyme
  • IgG1 and IgG4 both have their two heavy chains connected by two disulfide bonds and contain a total of 12 intra-chain disulfide bonds; however the light chain of IgG1 is linked to the heavy chain by a disulfide bond between the last residue of the light chain and the fifth cysteine residue of the heavy chain, while the light chain of IgG4 is linked to the heavy chain by a disulfide bond between the last cysteine residue of the light chain and the third cysteine residue of the heavy chain.
  • the level of solvent exposure is different between intra-chain and inter-chain disulfide bonds.
  • Intra-chain disulfide bonds are all buried between the secondary structures of each domain and are not solvent exposed.
  • the inter-chain disulfide bond including the inter-heavy-heavy-chain disulfide bond for IgG1 and IgG4, and the inter-heavy-light-chain disulfide bond for IgG1, which is located in the hinge region are highly solvent exposed.
  • the inter-heavy-light-chain disulfide bond for IgG4, which is located between the less accessible interface of VH and CH1 domains is not as much solvent exposed as a result.
  • Hinge region is a flexible linker between the Fab and the Fc of an antibody. Length and flexibility of the hinge region vary extensively among the IgG subclasses, IgG1, IgG2, IgG3, and IgG4. Taking IgG1 and IgG4 which are most commonly used as therapeutic biologics for example, the hinge region of IgG1 comprises 15 amino acids and is very flexible, while IgG4 has a shorter hinge with only 12 amino acids (Gestur Vidarsson, et al., IgG subclasses and allotypes: from structure to effector functions, Front. Immunol., 2014, 5: 520) .
  • Wild-type IgG1 and IgG4 differ by one amino acid in the core hinge region (226-229 by EU numbering) : Cys-Pro-Pro-Cys in IgG1 and Cys-Pro-Ser-Cys in IgG4.
  • Natural IgG4 presents an equilibrium between inter-and intra-chain cysteine disulfide bonds at the core hinge region, resulting in observable heavy chain arm exchange and the presence of IgG4 half molecules post secretion.
  • S228P mutation for IgG4 has been confirmed to markedly stabilize the covalent interaction between IgG4 heavy-chains by preventing natural arm exchange (S.
  • the S228P mutation results in a poly-proline helix in the IgG4 hinge (5 Pro in the lower hinge) , which when combined with the shorter IgG4 hinge length, will further restrict its flexibility compared to the IgG1 hinge (3 Pro in the lower hinge) .
  • the flexibility difference between different hinges has important implications for antibody bio-conjugation because the cysteine residues located in a flexible hinge fragment are considered more reactive than the ones located in a rigid hinge.
  • both S228P IgG4 inter-heavy-light-chain and inter-heavy-heavy-chain disulfide bonds are weakly reactive.
  • the disadvantage of utilizing natural cysteines for antibody conjugation is that the similarities of reactivity between four inter-chain disulfide bonds in IgG1 and IgG4, results in highly heterogeneous conjugation products. And as described, this heterogeneity narrows therapeutic window of conjugate drug in clinical use. For instance, ADC produced by partial reduction of native interchain disulfide bonds in IgG1 antibodies results in a mixture of products with normal distribution. Heterogeneity of product with partial reduction of IgG4 antibody is even higher, and lots of antibody remain un-reduced when the level of full reduced antibody already gets high.
  • WuXiBody TM (also referred to as “WuXiBody” herein below) is an innovative bispecific antibodies (bsAbs) platform developed by WuXi Biologics. Its key feature is replacing the CH1/CL constant domain in a Fab domain of an antibody with a T cell receptor (TCR) constant domain, as described in PCT application PCT/CN2018/106766 (published as WO2019/057122) .
  • WuXiBody TM design ensures cognate HC-LC pairing.
  • BsAbs based on WuXiBody can adopt either an asymmetric or a symmetric format. Heterodimerization can be ensured by the "Knobs-into-Holes" ( “KIH” ) technology.
  • the present disclosure provides an engineered antibody comprising a Fab domain with a TCR constant domain as in WuXiBody TM , an engineered hinge region and a Fc domain with KIH mutation. It is surprisingly found that ADCs produced with this engineered antibody have a high homogeneity and a well controlled DAR. These ADCs are advantageously characterized in high stability and excellent therapeutic efficacy.
  • an engineered dimeric antibody wherein the first monomer comprises a first Fab domain operably linked to a first engineered hinge region followed by an operably linked first Fc region, and the second monomer comprises a second Fab domain operably linked to a second hinge region followed by an operably linked second Fc region;
  • the first Fab domain is an antibody Fab domain
  • the second Fab domain comprises an antibody Fv domain fused to a TCR constant domain
  • the first engineered hinge region is composed of a portion of truncated IgG1 hinge region and a portion of truncated IgG4 hinge region or is a modified IgG4 hinge region, such that the hinge domain composed of the first engineered hinge region coupled with the second hinge region comprises at least two inter-chain disulfide bonds;
  • the Fc domain composed of the first Fc region coupled with the second Fc region comprises Knobs-into-Holes mutation.
  • nucleic acid molecule or a combination of nucleic acid molecules encoding the engineered antibody of the present invention is provided herein.
  • an antibody-drug conjugate comprising an engineered antibody of the invention conjugated to one or more drug molecules through a linker.
  • composition comprising or consisting of a mixture of antibody-drug conjugates of the invention, wherein at least about 65%, preferably at least about 70%, at least about 75%, at least about 80%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 2 (DAR2) .
  • DAR2 ratio of drug to antibody
  • composition comprising or consisting of a mixture of antibody-drug conjugates of the invention, wherein at least about 80%, preferably at least about 85%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 6 (DAR6) .
  • DAR6 ratio of drug to antibody being 6
  • a pharmaceutical composition comprising an antibody-drug conjugate of the invention and a pharmaceutically acceptable carrier.
  • a method of preparing the antibody-drug conjugate of the invention comprising a step of conjugating a partially reduced antibody of the invention with a linker-payload compound bearing a maleimido or haloacetyl moiety via Michael addition reaction.
  • an antibody-drug conjugate product obtained by the method of the invention, comprising or consisting of a mixture of antibody-drug conjugates of the invention, wherein least about 65%, preferably at least about 70%, at least about 75%, at least about 80%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 2.
  • an antibody-drug conjugate product obtained by the method of the invention, comprising or consisting of a mixture of antibody-drug conjugates of the invention, wherein at least about 80%, preferably at least about 85%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 6.
  • a method of treating a disease, disorder or condition in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of an antibody-drug conjugate of the invention.
  • the disease may be cancer.
  • an antibody-drug conjugate of the invention for use in treatment of a disease, disorder or condition in a subject in need thereof.
  • the disease may be cancer.
  • the present invention provides various advantages. Since native immunoglobulin G hinge sequences are used and swapped at their natural structural positions, without introduction of any de novo amino acid sequence, the engineered antibody will cause less immunogenicity in vivo. And, for the engineered antibodies, comparable protein expression titers can be obtained relative to their IgG1 or IgG4 counterparts. Furthermore, the engineered antibody allows obtaining highly homogeneous ADC products with a well controlled DAR.
  • ADC products according to the present invention advantageously have a high homogeneity of a well controlled DAR, such as a percentage of DAR2 species over 90% or a percentage of DAR6 species over 87%. Furthermore, The ADCs according to the present invention have excellent in vitro and in vivo stability.
  • Figure 1 A schematic diagram of an engineered antibody according to the present invention, and production of ADCs using same to produce DAR2 or DAR6 species as the main product.
  • Figure 2 shows the structure of antibody 886-39 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR2 is the main product.
  • Figure 3 shows the LC-MS characterization result of 886-39-MMAE-DAR2. According to the detected abundance of drug molecules attached on the light chains and the detected abundance of drug molecules attached on the heave chains, most of the drug molecules are loaded on the antibody Fab domain, and no drug is loaded on the TCR constant domain.
  • Figure 4 shows the structure of antibody 886-39 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR6 is the main product.
  • Figure 5 shows the LC-MS characterization result of 886-39-MMAE-DAR6. As the LC-MS result shows, no drug is loaded on the TCR constant domain.
  • Figure 6 shows the structure of antibody 886-40 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR2 is the main product.
  • Figure 7 shows the LC-MS characterization result of 886-40-MMAE-DAR2. According to the detected abundance of drug molecules attached on the light chains and the detected abundance of drug molecules attached on the heave chains, most of the drug molecules are loaded on the antibody Fab domain, and no drug is loaded on the TCR constant domain.
  • Figure 8 shows the structure of antibody 886-40 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR6 is the main product.
  • Figure 9 shows the LC-MS characterization result of 886-40-MMAE-DAR6. As the LC-MS result shows, no drug is loaded on the TCR constant domain.
  • Figure 10 shows the structure of antibody 886-41 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR2 is the main product.
  • Figure 11 shows the LC-MS characterization result of 886-41-MMAE-DAR2. According to the detected abundance of drug molecules attached on the light chains and the detected abundance of drug molecules attached on the heave chains, most of the drug molecules are loaded on the antibody Fab domain, and no drug is loaded on the TCR constant domain.
  • Figure 12 shows the structure of antibody 886-41 and the HIC-HPLC result of conjugation with MC-vc-PAB-MMAE. As the HIC-HPLC result shows, DAR6 is the main product.
  • Figure 13 shows the LC-MS characterization result of 886-41-MMAE-DAR6. As the LC-MS result shows, no drug is loaded on the TCR constant domain.
  • Figure 14 The light chain and the heavy chain sequences of the example antibodies, with the variable regions in bolds, the residues of KIH mutation in bolds and the engineered hinge region underlined.
  • LC refers to the light chain (LC) of the monomer comprising the antibody Fab domain
  • TCR-LC refers to the light chain (LC) of the monomer comprising the TCR constant domain in the Fab domain
  • TCR-HC-Knob refers to the heavy chain (HC) comprising Knob mutation in the Fc region
  • HC-Hole refers to the heavy chain (HC) comprising Hole mutation in the Fc region.
  • the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1%to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
  • the terms “about” or “approximately” when preceding a numerical value indicates the value plus or minus a range of 15%, 10%, 5%, or 1%.
  • the terms “substantially no” and “substantially free (of) " with regard to presence of a scenario or a substance not only refers to absence (i.e., “no” , “zero” or “free (of) " ) but also refers to a presence of insignificance or a presence or an amount below the limit of an assay and thus undetectable. This can be well understood by a skilled person in the art.
  • the terms “comprise” , “include” , “characterized by (in) ” and “have” , as well as their grammatical variants can be used interchangeably, which should be understood as including the specified step or element without excluding any other steps or elements. Accordingly, they encompasses the exclusive inclusion meant by the close-ended term “consist of” and its grammatical variants, and the semi-closed inclusion meant by the term “consist essentially of” that is only open to qualitatively and/or quantitatively insignificant elements.
  • an antibody encompasses any immunoglobulin, monoclonal antibody, polyclonal antibody, multispecific antibody, or bispecific (bivalent) antibody that binds to one or more specific antigens.
  • an antibody comprises two heavy chains and two light chains.
  • Each heavy chain comprises a variable region ( “VH” ) and a first, a second, a third constant regions (CH1, CH2, CH3) and conditionally a fourth constant region (CH4) as in the cases of IgM and IgE antibodies, while each light chain consists of a variable region ( “VL” ) and a constant region (CL) .
  • Mammalian heavy chains are classified as ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , and mammalian light chains are classified as ⁇ or ⁇ .
  • the variable regions of the light and the heavy chains are responsible for antigen binding.
  • Each variable region typically contains three highly variable loops called “complementarity determining regions (CDRs) " .
  • CDR boundaries can be defined or identified by the conventions of Kabat, Chothia, or Al-Lazikani.
  • the three CDRs are interposed between flanking stretches known as framework regions (FRs) , which are more highly conserved than the CDRs and form a scaffold to support the hypervariable loops.
  • the constant regions of the heavy and light chains are not involved in antigen binding, but exhibit various effector functions.
  • the five major classes of antibodies are IgA, IgD, IgE, IgG, and IgM, which are characterized by the presence of ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ heavy chains, respectively.
  • IgG1 ( ⁇ 1 heavy chain) IgG2 ( ⁇ 2 heavy chain)
  • IgG3 ( ⁇ 3 heavy chain) IgG4 ( ⁇ 4 heavy chain)
  • IgA1 ( ⁇ 1 heavy chain) ⁇ 2 heavy chain
  • IgA2 ( ⁇ 2 heavy chain) Several of the major antibody classes are divided into subclasses such as IgG1 ( ⁇ 1 heavy chain) , IgG2 ( ⁇ 2 heavy chain) , IgG3 ( ⁇ 3 heavy chain) , IgG4 ( ⁇ 4 heavy chain) , IgA1 ( ⁇ 1 heavy chain) , or IgA2 ( ⁇ 2 heavy chain) .
  • IgG isotype e.g, "IgG1" or “IgG1 isotype”
  • IgG isotypes refer to IgG isotypes of the defined subclass
  • different IgG isotypes refer to IgG isotypes of different subclasses.
  • variable region refers to an antibody variable region or a fragment thereof comprising one or more CDRs.
  • a variable region may comprise an intact variable region (such as VH or VL) , it is also possible to comprise less than an intact variable region yet still retain the capability of binding to an antigen or forming an antigen-binding site.
  • the antibody may have a “Y” shape, wherein the two arms are also known as “Antigen-binding Fragments (Fab) " , and the stem portion comprises the hinge domain and the Fc domain of the antibody.
  • Fab Antigen-binding Fragments
  • Fab fragment
  • Fab arm can be used interchangeably, which refer to the domain consisting of a light chain coupled with a heavy chain along the variable region and first constant region in an immunoglobulin (e.g., an antibody) .
  • the Fab domain may comprise one or more inter-chain disulfide bonds.
  • the constant regions of both the light chain and the heavy chain can be replaced with TCR constant regions.
  • the Fab domain is responsible for various antigen binding activities.
  • Fc region refers to the fragment consisting of the second (CH2) and the subsequent constant regions of a heavy chain, or refers to the fragment consisting of a portion of the hinge region, the second (CH2) and the subsequent constant regions of a heavy chain.
  • Fc domain in context of a dimeric antibody refers to the portion of the coupled heavy chains along the Fc region of each.
  • the Fc regions have various effector functions such as ADCC, and CDC.
  • the term "hinge” or “hinge region” of a heavy chain refers to the region that connects the C-terminus of the CH1 to the N-terminus of the CH2 region of the heavy chain.
  • a hinge region may have a length of about 12-62 amino acid residues. In human IgG1, the hinge region spans residues 216 to 230 by EU numbering, and in human IgG4 from residues 219 to 230 by EU numbering.
  • the term "hinge domain” in context of a dimeric antibody refers to the portion of the coupled heavy chains along the hinge region of each. Typically, the hinge domain may comprise one, two or more inter-chain disulfide bonds. Hinge regions are flexible, thus allowing the two Fab domains to move independently.
  • Hinge region is a flexible linker between the Fab and the Fc of antibody. Length and flexibility of the hinge region varies extensively among the IgG subclasses, IgG1, IgG2, IgG3, and IgG4. Taking IgG1 and IgG4 which are most commonly used as therapeutic biologics for example, the hinge region of IgG1 comprises 15 amino acids (e.g., EPKSCDKTHTCPPCP (SEQ ID NO: 9) ) and is very flexible, while IgG4 has a shorter hinge with only 12 amino acids .
  • EPKSCDKTHTCPPCP SEQ ID NO: 9
  • Wild-type IgG1 and IgG4 differ by one amino acid in the core hinge region (226-229 by EU numbering) : Cys-Pro-Pro-Cys in IgG1 and Cys-Pro-Ser-Cys in IgG4.
  • Natural IgG4 presents an equilibrium between inter-and intra-chain cysteine disulfide bonds at the core hinge region, resulting in observable heavy chain arm exchange and the presence of IgG4 half molecules post secretion.
  • S228P mutation for IgG4 e.g., ESKYGPPCPPCP (SEQ ID NO: 10) ) has been confirmed to markedly stabilize the covalent interaction between IgG4 heavy-chains by preventing natural arm exchange, thus widely applied in IgG4 antibody development and production.
  • the S228P mutation results in a poly-proline helix (PPCPPCP) in the IgG4 hinge, which when combined with the shorter IgG4 hinge length, will further restrict its flexibility compared to the IgG1 hinge.
  • PPCPPCP poly-proline helix
  • CH2 domain refers to the portion of a heavy chain molecule that extends, e.g., from about amino acid 244 to amino acid 360 of an IgG antibody using conventional numbering schemes (amino acids 244 to 360, Kabat numbering system; and amino acids 231-340, EU numbering system) .
  • the “CH3 domain” extends from the CH2 domain to the C-terminus of the IgG molecule and comprises approximately 108 amino acids.
  • Fv Fv fragment
  • Fv domain Fv domain
  • VL variable region of the light chain
  • VH variable region of the heavy chain
  • Percentage (%) of identity between biological sequences is defined as the percentage of identical residues between a query sequence and a reference sequence according to an alignment for maximum matching. Sequence identity can be determined using publicly available tools, such as BLASTN, BLASTp (available on the website of U.S. National Center for Biotechnology Information (NCBI) , ClustalW2 (available on the website of European Bioinformatics Institute) , and ALIGN or Megalign (DNASTAR) software.
  • BLASTN BLASTN
  • BLASTp available on the website of U.S. National Center for Biotechnology Information (NCBI)
  • ClustalW2 available on the website of European Bioinformatics Institute
  • ALIGN Megalign
  • the term “specific binding” or “specifically bind” refers to a non-random binding reaction between two molecules, such as between an antibody and an antigen.
  • an engineered antibody provided herein may specifically bind to an antigen with a binding affinity (K D ) of ⁇ 10 -6 M (e.g., ⁇ 5x10 -7 M, ⁇ 2x10 -7 M, ⁇ 10 -7 M, ⁇ 5x10 -8 M, ⁇ 2x10 -8 M, ⁇ 10 -8 M, ⁇ 5x10 -9 M, ⁇ 2x10 -9 M, ⁇ 10 -9 M, or ⁇ 10 -10 M) .
  • K D refers to the ratio of the dissociation rate to the association rate (k off /k on ) .
  • operably link refers to a juxtaposition, with or without a spacer or linker, of two or more biological sequences of interest in such a way that they are in a relationship permitting them to function in an intended manner.
  • polypeptides it is intended to mean that the polypeptide sequences are linked in such a way that permits the linked product to have the intended biological function.
  • an antibody variable region may be operably linked to a constant region so as to provide for a stable product with antigen-binding activity.
  • the term may also be used with respect to polynucleotides.
  • a polynucleotide encoding a polypeptide when operably linked to a regulatory sequence (e.g., promoter, enhancer, silencer sequence, etc. ) , it is intended to mean that the polynucleotide sequences are linked in such a way that permits regulated expression of the polypeptide from the polynucleotide.
  • a regulatory sequence e.g., promoter, enhancer, silencer sequence, etc.
  • a sequence less than 100%identical to a reference sequence may comprise mutation at one or more positions, wherein the mutation can be substitution, addition, deletion or a combination thereof.
  • the substitution may be a “conservative substitution” , which refers to replacement with a different amino acid having a side chain of similar physiochemical properties or substitution at a site not critical to the activity or function of the sequence.
  • conservative substitutions can be a replacement between amino acids with a nonpolar side chain (e.g., Met, Ala, Val, Leu, and Ile, Pro, Phe, Trp) , between amino acids with an uncharged polar side chain (e.g., Cys, Ser, Thr, Asn, Gly and Gln) , between amino acids with an acidic side chain (e.g., Asp, Glu) , between amino acids with a basic side chain (e.g., His, Lys, and Arg) , between amino acids with a beta-branched side chain (e.g., Thr, Val and Ile) , between amino acids with a sulfur-containing side chain (e.g., Cys and Met) , or between amino acids with an aromatic side chain (e.g., Trp, Tyr, His and Phe) .
  • Conservative substitution does not cause a significant change in conformational structure, and therefore could retain the biological activity of a protein.
  • the term “subject” refers to a human or a non-human animal subject.
  • Non-human animals may be mammals, such as primates. Examples of non-human animal subjects include but are not limited to domestic animals, farm animals, and zoo, sports, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, swine, cows, and bears.
  • the subject is a human.
  • a "subject in need thereof” refers to a subject in need of diagnosis, prognosis, amelioration, prevention and/or treatment of a disease, disorder or condition.
  • an engineered dimeric antibody wherein the first monomer comprises a first Fab domain operably linked to a first engineered hinge region followed by an operably linked first Fc region, and the second monomer comprises a second Fab domain operably linked to a second hinge region followed by an operably linked second Fc region;
  • the first Fab domain is an antibody Fab domain
  • the second Fab domain comprises an antibody Fv domain fused to a TCR constant domain
  • the first engineered hinge region is composed of a portion of truncated IgG1 hinge region and a portion of truncated IgG4 hinge region or is a modified IgG4 hinge region, such that the hinge domain composed of the first engineered hinge region coupled with the second hinge region comprises at least two inter-chain disulfide bonds;
  • the Fc domain composed of the first Fc region coupled with the second Fc region comprises Knobs-into-Holes mutation.
  • the engineered antibody of the invention can be schematically depicted as in FIG. 1, wherein the TCR constant domain is indicated by a pair of rectangles.
  • the dimeric antibody is formed of the monomers coupled by inter-chain bonding, including inter-chain bonds and/or interactions. Examples of such inter-chain bonding include but are not limited to disulfide bonds, hydrogen bonds, electrostatic interaction, salt bridges, hydrophobic-hydrophilic interaction and Knobs-into-Holes mechanism.
  • the engineered antibody of the invention is a heterodimer.
  • antibody Fab domain has the standard meaning as commonly understood by a skilled person in the art, which refers to a Fab domain having the typical architecture and functionality of the Fab domain in an immunoglobulin as commonly recognized and classified as an antibody. Particularly, in context of the present invention, it can also be conveniently understood at a typical Fab domain not having its constant domain replaced with a TCR constant domain according to the WuXiBody TM technology.
  • the antibody Fab domain may derive from any antibodies, especially those that are clinically relevant.
  • the antibody Fab domain derives from an antibody that specifically binds to a tumor antigen (TA) , such as a tumor specific antigen (TSA) and a tumor-associated antigen (TAA) .
  • TA tumor antigen
  • TSA tumor specific antigen
  • TAA tumor-associated antigen
  • tumor antigen examples include, but are not limited to, CD20, CD38, CD123, ROR1, ROR2, BCMA, PSMA, SSTR2, SSTR5, CD19, FLT3, CD33, PSCA, ADAM 17, CEA, Her2, EGFR, EGFR-vIII, CD30, FOLR1, GD-2, CA-IX, Trop-2, CD70, CD38, mesothelin, EphA2, CD22, CD79b, GPNMB, CD56, CD138, CD52, CD74, CD30, CD123, RON, and ERBB2.
  • TA-specific antibodies include, but are not limited to, Trastuzumab, Rituximab, Cetuximab, Bevacizumab, Panitumumab, Alemtuzumab, Matuzuma, Gemtuzumab, Polatuzumab, Inotuzumab, etc.
  • an antibody Fv domain is fused to a TCR constant domain according to the WuXiBody TM technology as described in PCT/CN2018/106766.
  • the heavy chain variable region (VH) is fused to a TCR constant region in the heavy chain and the light chain variable region (VL) fused to the other TCR constant region in the light chain.
  • the term "antibody Fv" domain refers to the Fv domain of an antibody Fab as described above.
  • the first Fab domain and the second Fab domain may have identical or different binding specificities.
  • the TCR constant domain may be composed of the pairing C ⁇ and C ⁇ regions or the pairing C ⁇ and C ⁇ regions of TCRs.
  • the TCR constant domain is a C ⁇ constant domain.
  • the second monomer is the TCR constant domain-comprising half-antibody of a WuXiBody TM antibody.
  • the TCR constant domain also has an inter-chain disulfide bond, it is much less reducible and thus much less available for drug conjugation than the inter-chain disulfide bond in an antibody Fab domain.
  • the present invention takes advantage of this difference in reducibility to enable production of ADCs with a high homogeneity and a better controlled DAR.
  • the antibody Fab domain is one of an IgG1 antibody, i.e., one of IgG1 isotype.
  • the antibody Fab domain is one of a human IgG1 antibody.
  • the Fv domain is one of an IgG antibody, i.e., one of IgG class, preferably human IgG class.
  • the engineered antibody of the invention characteristically comprises an engineered hinge region in the first monomer, i.e., the "first engineered hinge region" , which is composed of a portion of truncated IgG1 hinge region and a portion of truncated IgG4 hinge region or is a modified IgG4 hinge region, such that the hinge domain composed of the first engineered hinge region coupled with the second hinge region comprises at least two inter-chain disulfide bonds.
  • the engineered hinge region is constituted with natural acids and comprises cysteine residues for forming the at least two inter-chain disulfide bonds between the heavy chains.
  • the wild-type hinge region of IgG1 comprises 15 amino acids (e.g., EPKSCDKTHTCPPCP (SEQ ID NO: 9) ) and is very flexible, while IgG4 has a shorter hinge with only 12 amino acids (supra) .
  • Wild-type IgG1 and IgG4 differ by one amino acid in the core hinge region (226-229 by EU numbering) : Cys-Pro-Pro-Cys in IgG1 and Cys-Pro-Ser-Cys in IgG4, IgG hinge with S228P mutation may be represented by the sequence of ESKYGPPCPPCP (SEQ ID NO: 10) .
  • the S228P mutation results in a poly-proline helix (PPCPPCP) in the IgG4 hinge, which when combined with the shorter IgG4 hinge length, will further restrict its flexibility compared to the IgG1 hinge.
  • PPCPPCP poly-proline helix
  • engineered hinge region offers an improved payload-antibody ratio (PAR, equivalent to DAR) during bio-conjugation, taking advantage of differential accessibility by a reductant among the inter-chain disulfides in the hinge domain and the Fab domains.
  • PAR payload-antibody ratio
  • engineered antibodies with the engineered hinge region provide various advantages in ADC production and the ADC product per se, such as a high homogeneity, a better controlled DAR, simplified production, desirable pharmacokinetic properties and/or pharmcodynamic properties.
  • the engineered hinge region may comprise a sequence having the following formula (I) :
  • the engineered hinge region comprises a sequence of formula EPKx 1 C x 2 x 3 x 4 x 5 x 6 PPCPPCP. In some embodiments, the engineered hinge region comprises a sequence of formula EPKSC x 2 x 3 x 4 x 5 x 6 PPCPPCP.
  • Preferred examples of the engineered hinge region include:
  • the engineered hinge region may further comprise an additional hinge segment (e.g., an upper hinge region segment) at either or both sides of the designated region.
  • an additional hinge segment e.g., an upper hinge region segment
  • the term "hinge domain” refers to the portion of the coupled heavy chains along the hinge region of each.
  • the first and the second hinge regions in the two heavy chains are aligned from the N-terminal of each as described in PCT/CN2018/106766.
  • the second hinge region in the second monomer can be a native or also an engineered TCR hinge region or antibody hinge region or a hybrid thereof.
  • the engineered antibody of the invention comprises a Fc domain comprising Knobs-into-Holes mutation to facilitate heterodimerization.
  • the Fc domain is a human Fc domain.
  • the Fc domain is an IgG Fc domain, i.e., one of IgG class, and more preferably, one of IgG1 or IgG4 isotype.
  • the Fc domain has KIH mutations for heterodimerization according to the KIH mechanism.
  • Knobs-into-Holes ( “KIH” ) is known as a mechanism to ensure high heterodimerization. It refers to amino acid engineering that creates steric influences to favor heterodimeric formation and disfavor homodimeric formation can also optionally be used; this is sometimes referred to as “knobs and holes” .
  • the first Fc region i.e., the Fc region in the antibody Fab domain-comprising first monomer
  • the second Fc region i.e., the Fc region in the second monomer comprising the replacement with TCR constant domain in the second Fab domain, comprises Knob mutation. This further facilitates heterodimerization to avoid mismatching between the two monomers and to provide the WuXiBody TM architecture as desired.
  • the engineered antibody of the invention may comprise a set of four chains according to the following (a) , (b) or (c) :
  • a first light chain comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having an identity of at least 85%to SEQ ID NO: 15,
  • a second heavy chain comprising the amino acid sequence of SEQ ID NO: 14 or a sequence having an identity of at least 85%to SEQ ID NO: 14, and
  • a second light chain comprising the amino acid sequence of SEQ ID NO: 16 or a sequence having an identity of at least 85%to SEQ ID NO: 16;
  • a first light chain comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having an identity of at least 85%to SEQ ID NO: 15,
  • a second heavy chain comprising the amino acid sequence of SEQ ID NO: 14 or a sequence having an identity of at least 85%to SEQ ID NO: 14, and
  • a second light chain comprising the amino acid sequence of SEQ ID NO: 16 or a sequence having an identity of at least 85%to SEQ ID NO: 16;
  • a first light chain comprising the amino acid sequence of SEQ ID NO: 15 or a sequence having an identity of at least 85%to SEQ ID NO: 15,
  • a second heavy chain comprising the amino acid sequence of SEQ ID NO: 14 or a sequence having an identity of at least 85%to SEQ ID NO: 14, and
  • a second light chain comprising the amino acid sequence of SEQ ID NO: 16 or a sequence having an identity of at least 85%to SEQ ID NO: 16;
  • first heavy chain and light chain form the first monomer and the second heavy chain and light chain form the second monomer.
  • nucleic acid molecule or a combination of nucleic acid molecules encoding the engineered antibody of the present invention encodes one or more of the sequences of SEQ ID NOs: 11 and 14 to 16, or sequences having an identity of at least 85%to anyone of SEQ ID NOs: 11 and 14 to 16; one or more of the sequences of SEQ ID NOs: 12 and 14 to 16, or sequences having an identity of at least 85%to anyone of SEQ ID NOs: 12 and 14 to 16; or one or more of the sequences of SEQ ID NOs: 13 and 14 to 16, or sequences having an identity of at least 85%to anyone of SEQ ID NOs: 13 and 14 to 16.
  • the nucleic molecule or molecules may be provided in the form of one or more vectors, especially expression vectors.
  • nucleic acids encoding the heavy chains and the light chains of an antibody can be cloned into separate expression vectors and co-transferred into a host to recombinantly produce the antibody, and it is also possible to insert the coding sequences for the chains in one expression vector.
  • Any expression vectors and hosts known in the field are useful for the present invention. Examples include but are not limited to plasmids, viral vectors, synthetic vectors, bacteria hosts, yeasts, insect cells and animal cells, such as CHO cells.
  • said nucleic acid molecule or a combination of nucleic acid molecules, like vectors may be provided in the form of a kit, which may optionally comprises instruction on using the nucleic acid molecule or molecules to recombinantly produce the antibody.
  • an antibody-drug conjugate comprising the engineered antibody of the invention conjugated to one or more drug molecules through a linker.
  • the engineered antibody of the invention comprises a first Fab domain being an antibody Fab domain and a second Fab domain comprising the Fv domain fused to a TCR constant domain.
  • the first Fab domain and the second Fab domain may have identical or different binding specificities, and the antibody Fab domain and the Fv domain may independently derive from any antibodies, especially those that are clinically relevant, such as those specifically binding to a tumor antigen (TA) , such as a tumor specific antigen (TSA) and a tumor-associated antigen (TAA) supra.
  • TA tumor antigen
  • TSA tumor specific antigen
  • TAA tumor-associated antigen
  • the drug (also known as "payload” ) used in the present invention is not particularly limited.
  • Drugs for use in the present invention include cytotoxic drugs, particularly those which are used for cancer therapy.
  • Such drugs include, but are not limited to, DNA damaging agents, DNA binding agents, anti-metabolites, enzyme inhibitors such as thymidylate synthase inhibitors and topoisomerase inhibitors, tubulin inhibitors, and toxins (for example, toxins of a bacterial, fungal, plant or animal origin) .
  • taxol methotrexate, methopterin, dichloromethotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, melphalan, leurosine, leurosideine, actinomycin, daunorubicin, doxorubicin, mitomycin C, mitomycin A, caminomycin, aminopterin, tallysomycin, podophyllotoxin and podophyllotoxin derivatives such as etoposide or etoposide phosphate, vinblastine, vincristine, vindesine, taxanes including taxol, taxotere retinoic acid, butyric acid, N8-acetyl spermidine, camptothecin, calicheamicin, esperamicin, ene-diynes, duocarmycin A, duocarmycin SA, calicheamicin, camptothecin, hemiasterlin
  • auristatins eg., MMAE
  • Drugs can be linked to the linker via any suitable methods known in the art.
  • the drug is provided for conjugation in the form of a linker-payload compound as an intermediate, like in the case of "MC-vc-PAB-MMAE" .
  • the drug used in the present invention can be bound to an antibody via a linker.
  • linkers for ADCs are known in the art.
  • Linkers useful in the present invention are not particularly limited, as long as it includes a moiety capable reacting with a thoil group rendered by an antibody and thereby linking to the antibody.
  • Particularly useful in the present invention are amleimido or haloactyl functionalized linkers.
  • Examples include, but are not limited to -MC-vc-PAB- ( “MC” : Maleimide-caproyl; “-vc-” : the dipeptide of -Val-Cit-; “PAB” : para-aminobenzyl) , -MC-GGFG- ( "-GGFG-” : the tetrapeptide of –Gly-Gly-Phe-Gly-) , -MC-vc-, -MC-and -SMCC- (succinimidyl-4- (N-maleimidomethyl) cyclohexane-1-carboxylate) .
  • the linker is -MC-vc-PAB-.
  • the linker-payloads are connected to the cysteine residues provided by selected inter-chain disulfide bonds opened by reduction.
  • the conjugate of the invention may have a ratio of drug to antibody (DAR) ranging from about 2 to about 6, and preferably about 2 or about 6. The ratio may refer to an average ratio in a population, such as an average of DAR2 or DAR6 for a population of ADCs.
  • the conjugate has two drug molecules all linked at the antibody Fab domain and substantially no drug molecules linked at the TCR constant domain.
  • the conjugate has six drug molecules all linked at the antibody Fab domain and the hinge domain, and substantially no drug molecules linked at the TCR constant domain.
  • composition comprising or consisting of a mixture of antibody-drug conjugates according to the invention, wherein least about 65%, preferably at least about 70%, at least about 75%, at least about 80%or at least about 90%of the mixture have a DAR of 2 (i.e., DAR2) .
  • DAR2 a DAR of 2
  • the conjugates of DAR2 have the two drug molecules all linked at the antibody Fab domain and substantially no drug molecules linked at the TCR constant domain.
  • compositions comprising or consisting of a mixture of antibody-drug conjugates according to the invention, wherein, at least about 80%, preferably at least about 85%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 6 (i.e., DAR6) .
  • DAR6 a ratio of drug to antibody being 6
  • the conjugates of DAR6 have the six drug molecules all linked at the antibody Fab domain and the hinge domain, and substantially no drug molecules linked at the TCR constant domain.
  • a pharmaceutical composition comprising the antibody-drug conjugate or the mixture thereof as described above and a pharmaceutically acceptable carrier.
  • the ADCs of the invention can be prepared using any suitable methods known in this field.
  • linker-payloads are conjugated at cysteine residues freed from disulfide bonds via reduction using a mild reductant.
  • the engineered hinge region according to the invention alters reducibility of the disulfide bonds in the hinge domain, which leads to selective reduction of disulfide bonds, when the antibody is partially reduced using a mild reductant.
  • introducing a TCR constant domain in one of the Fab domains also facilitates control of DAR of an ADC product.
  • the present invention advantageously provides a highly homogeneous ADC product with a well controlled DAR, comprising predominantly conjugates with two linker-payloads attached at the antibody Fab domain or comprising predominantly conjugates with six linker-payloads attached at the antibody Fab domain and the hinge domain, with substantially no linker-payloads attached at the TCR constant domain.
  • the method may involve partial reduction of the antibody and conjugation between the partially reduced antibody and a linker-payload, as schematically depicted in figure 1.
  • the conjugation is conducted in a reduction buffer with an organic solvent as additive to help dissolve the linker-payload.
  • the method may comprise a step of conjugating a partially reduced antibody of the invention with a linker-payload compound bearing a maleimido or haloacetyl moiety via Michael addition reaction.
  • the partially reduced antibody may be produced by partially reducing an engineered antibody of the invention using a mild reductant.
  • the method may comprise:
  • the mild reductant is TCEP or DTT.
  • the reductant/antibody ratio is about 1 to 20, preferably about 2 to 15, and more preferably about 3 to 10.
  • the partial reduction is conducted at pH of about 4.0 to 8.0, preferably about 5 to 7.
  • the partial reduction is conducted for a period of about 0.5 to 24 hours (hr) , preferably about 1 to 24 hours, about 1 to 16, about 10 to 24 or about 16 to 24 hours.
  • the partial reduction is conducted at a temperature of about 4 to 37 °C, preferably about 4 to 15 °C or about 4 to 10 °C.
  • the method provides a product comprising or consisting of a mixture of antibody-drug conjugates according to the invention, wherein least about 65%, preferably at least about 70%, at least about 75%, at least about 80%or at least about 90%of the mixture have a DAR of 2.
  • the conjugates of DAR2 have the two drug molecules all linked at the antibody Fab domain and substantially no drug molecules linked at the TCR constant domain.
  • the mild reductant is TCEP or DTT.
  • the reductant/antibody ratio is about 1 to 20, preferably about 3 to 20, about 3 to 10 or about 10 to 20.
  • the partial reduction is conducted at pH of about 4.0 to 8.0, preferably about 6 to 8.
  • the partial reduction is conducted for a period of about 0.5 to 24 hours (hr) , preferably about 3 to 24 hours, about 3 to 16, about 10 to 24 or about 16 to 24 hours.
  • the partial reduction is conducted at a temperature of about 4 to 37°C, preferably about 4 to 15°C or about 4 to 10 °C.
  • the method provides a product comprising or consisting of a mixture of antibody-drug conjugates according to the invention, wherein, at least about 80%, preferably at least about 85%or at least about 90%of the antibody-drug conjugates have a ratio of drug to antibody being 6 (i.e., DAR6) .
  • the conjugates of DAR6 have the six drug molecules all linked at the antibody Fab domain and the hinge domain, and substantially no drug molecules linked at the TCR constant domain.
  • the conjugation is carried out in a buffer of pH ranging from about 4.0 to 8.0, optionally in presence of an organic additive (e.g., organic solvent or organic co-solvent) at an amount of about 0.0%to 20.0%by weight, preferably about 5.0%to 15.0%or about 10.0%to 15.0%.
  • an organic additive e.g., organic solvent or organic co-solvent
  • the drug/antibody ratio may be about 7 to 20, preferably about 7 to 10;
  • the reaction temperature may be about 4 to 37°C, preferably about 4 to 20°C or about 4 to 10°C; and/or the time of reaction may be about 0.5 to 4 hours, preferably about 1 to 3 hours.
  • the antibody-drug conjugate of the invention can be used for treating a disease, disorder or condition in a subject in need thereof, wherein the treatment may comprise administrating to the subject a therapeutically effective amount of the antibody drug-conjugate.
  • an antibody-drug conjugate according to the present invention for use in treatment of a disease, disorder or condition in a subject in need thereof.
  • the disease to be treated may include but are not be limited to cancers, including solid tumors and hematopoeitic malignancies.
  • cancers include but are not limited to breast cancers, gastric cancers, pancreatic cancers, hepatic cancers, lung cancers (e.g., NSCLC) , head and neck cancers, colorectal cancers, B cell lymphomas (e.g., non-Hodgkin’s lymphoma (NHL) ) and leukemia.
  • NSCLC non-Hodgkin’s lymphoma
  • ADC Antibody-drug conjugate
  • EGFR Epidermal growth factor receptor
  • FGE Formylglycine-generating enzyme
  • IC50 The half maximal inhibitory concentration
  • IgG Immunoglobulin G
  • MMAE Monomethyl auristatin E
  • NNAA Non-natural amino acid
  • PAB para-aminobenzyl
  • TCEP Tris (2-carboxyethyl) phosphine
  • VH Variable region of heavy chain
  • CHO K1 host cells were seeded at 2-4E5 cells/mL in CD CHO medium 72 hours before transfection. The host cells were counted for cell density using Vi-CELL, centrifuged at 290 g for 7 min and then resuspended in pre-warmed fresh CD CHO medium prior to transfection. The re-suspended host cells were incubated in a Kuhner shaker (36.5°C, 75%humidity, 6%CO 2 , 120 rpm) before use.
  • a total 4 mg of plasmids encoding the antibody of interest were added into the re-suspended host cells, followed by 12 mg polyetherimide.
  • the transfected cultures were incubated in a Kuhner shaker at 36.5°C, 75%humidity, 6%CO 2 , 120 rpm for 4 hours. After proprietary supplements were added, the transfected cultures were then incubated in a Kuhner shaker at 31°C, 75%humidity, 6%CO 2 , 120 rpm for 9-10 days.
  • transfected cultures were clarified by primary centrifugation at 1,000 g for 10 min, and secondary centrifugation at 10,000 g for 40 min, followed by sterile filtration through 0.22 ⁇ m filter.
  • the supernatants were measured for titers and purified by ProA chromatography.
  • the ProA eluate were neutralized by adding 1-2%neutralization buffer (1 M Tris-HCl, pH 9.0) and formulated in 20 mM Histidine-Acetate buffer, pH 5.5.
  • All proteins were subjected to quality control tests before conjugation, including reducing and non-reducing SDS-PAGE, SEC-HPLC, endotoxin level detection by LAL gel clot assay and molecular identification by mass spectrometry.
  • organic co-solvent such as DMA was added to the partial reduced antibody to a concentration of 0%to 20%, with 7-20eq of Maleimido or Haloacetyl functionalized linker-payload.
  • the conjugation was performed at 4-37°C for 0.5hr to 4hr with gentle shaking or stirring (Fig. 1) .
  • Final conjugated product was characterized with UV-vis for concentration, HIC-HPLC for conjugate distribution and DAR, LC-MS for drug loading on light chain and heave chain, RP-HPLC for free drug residue, SEC-HPLC for aggregation and purity, and kinetic turbidimetric for Endotoxin level.
  • Anti-Her2 antibody 886-39 (IgG-TCR, IgG1-Fab, IgG4-Fc) , also referred to as "WBP886-39" in FIG. 14, was constructed using the engineered hinge region of sequence EPKSCSKYGPPCPPCP (SEQ ID NO: 2) . It has the first light chain (LC) sequence of SEQ ID NO: 15, the first heavy chain (HC) sequence of SEQ ID NO: 11, the second LC sequence of SEQ ID NO: 16 and the second HC sequence of SEQ ID NO: 14.
  • the first LC and HC form the monomer having the antibody Fab and the Fc region with the "Hole” mutation
  • the second LC and HC form the monomer having the TCR constant domain replacement in the Fab domain and having the "Knob” mutation in the Fc region.
  • the antibody was recombinantly produced as described in the part of general method.
  • the antibody was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 8.66mg/ml.
  • the formulation buffer was changed to PBS pH7.0 and the concentration was 4mg/ml.
  • 2.0eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16hr.
  • DMA was added to the reduced antibody to a concentration of 10%, followed by 7eq of MC-vc-PAB-MMAE.
  • Conjugation reaction was performed at 4°C for 1hr.
  • the conjugated product was purified with 40KD MWCO desalting column and stored in PBS pH 7.0.
  • Final product was characterized with HIC-HPLC for DAR and drug distribution determination, LC-MS for conjugation site determination (Fig. 2 and Fig. 3) .
  • HIC-HPLC result of DAR and drug distribution is shown below:
  • Anti-Her2 antibody 886-40 (IgG-TCR, IgG1-Fab, IgG4-Fc) , also referred to as "WBP886-40" in FIG. 14, was constructed using the engineered hinge region of sequence EPKSCKYGPPCPPCP (SEQ ID NO: 3) . It has the first light chain (LC) sequence of SEQ ID NO: 15, the first heavy chain (HC) sequence of SEQ ID NO: 12, the second LC sequence of SEQ ID NO: 16 and the second HC sequence of SEQ ID NO: 14.
  • the first LC and HC form the monomer having the antibody Fab and the Fc region with the "Hole” mutation
  • the second LC and HC form the monomer having the TCR constant domain replacement in the Fab domain and having the "Knob” mutation in the Fc region.
  • the antibody was recombinantly produced as described in the part of general method.
  • the antibody was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 10.83mg/ml.
  • the formulation buffer was changed to PBS pH7.0 and the concentration was 4mg/ml.
  • 2.0eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16 hr.
  • DMA was added to the reduced antibody to a concentration of 10%, followed by 7eq of MC-vc-PAB-MMAE.
  • Conjugation reaction was performed at 4°C for 1hr.
  • the conjugated product was purified with 40KD MWCO desalting column and stored in PBS pH 7.0.
  • Final product was characterized with HIC-HPLC for DAR and drug distribution determination, LC-MS for conjugation site determination (Fig. 6 and Fig. 7) .
  • HIC-HPLC result of DAR and drug distribution is shown below:
  • Anti-Her2 antibody 886-41 (IgG-TCR, IgG1-Fab, IgG4-Fc) , also referred to as "WBP886-41" in FIG. 14, was constructed using the engineered hinge region of sequence EPKSCYGPPCPPCP (SEQ ID NO: 4) . It has the first light chain (LC) sequence of SEQ ID NO: 15, the first heavy chain (HC) sequence of SEQ ID NO: 13, the second LC sequence of SEQ ID NO: 16 and the second HC sequence of SEQ ID NO: 14.
  • the first LC and HC form the monomer having the antibody Fab and the Fc region with the "Hole” mutation
  • the second LC and HC form the monomer having the TCR constant domain replacement in the Fab domain and having the "Knob” mutation in the Fc region.
  • the antibody was recombinantly produced as described in the part of general method.
  • the antibody was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 4mg/ml. 14.0eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16hr. Then DMA was added to the reduced antibody to a concentration of 10%, followed by 7eq of MC-vc-PAB-MMAE. Conjugation reaction was performed at 4°C for 1hr. The conjugated product was purified with 40KD MWCO desalting column and stored in 20mM Histidine pH 5.5. Final product was characterized with HIC-HPLC for DAR and drug distribution determination, LC-MS for conjugation site determination (Fig. 10 and Fig. 11) . HIC-HPLC result of DAR and drug distribution is shown below:
  • Anti-Her2 antibody 886-39 was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 8.66mg/ml.
  • the formulation buffer was changed to PBS pH8.0 and the concentration was 4mg/ml.
  • 12eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16hr.
  • DMA was added to the reduced antibody to a concentration of 10%, followed by 13eq of MC-vc-PAB-MMAE. Conjugation reaction was performed at 4°C for 1hr.
  • the conjugated product was purified with 40KD MWCO desalting column and stored in 20mM Histidine-acetate pH 5.5.
  • Final product was characterized with HIC-HPLC for DAR and drug distribution determination, LC-MS for conjugation site determination (Fig. 4 and Fig. 5) .
  • HIC-HPLC result of DAR and drug distribution is shown below:
  • Anti-Her2 antibody 886-40 was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 10.83mg/ml.
  • the formulation buffer was changed to PBS pH8.0 and the concentration was 4mg/ml.
  • 14.0eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16hr.
  • DMA was added to the reduced antibody to a concentration of 10%, followed by 17eq of MC-vc-PAB-MMAE. Conjugation reaction was performed at 4°C for 1hr.
  • the conjugated product was purified with 40KD MWCO desalting column and stored in 20mM Histidine-acetate pH 5.5. Final product was characterized with HIC-HPLC for DAR and drug distribution determination (Fig. 8 and Fig. 9) .
  • HIC-HPLC result of DAR and drug distribution is shown below:
  • Anti-Her2 antibody 886-41 was dissolved in 20mM Histidine, 150mM NaCl, pH 5.5 to a concentration of 10.40mg/ml.
  • the formulation buffer was changed to PBS pH8.0 and the concentration was 4mg/ml.
  • 16.0eq of TCEP was added to the antibody solution and the mixture was incubated at 4°C for 16hr.
  • DMA was added to the reduced antibody to a concentration of 10%, followed by 19eq of MC-vc-PAB-MMAE. Conjugation reaction was performed at 4°C for 1hr.
  • the conjugated product was purified with 40KD MWCO desalting column and stored in 20mM Histidine-acetate pH 5.5. Final product was characterized with HIC-HPLC for DAR and drug distribution determination (Fig. 12 and Fig. 13) .
  • HIC-HPLC result of DAR and drug distribution is shown below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un anticorps dimérique modifié qui comprend un premier domaine Fab qui est un Fab d'anticorps, un second domaine Fab comprenant un domaine constant de TCR, un domaine de charnière modifié et un domaine Fc avec une mutation "noeuds dans la cavité" (knob-into-holes). L'invention concerne également un conjugué anticorps-médicament comprenant l'anticorps modifié conjugué à une ou plusieurs molécules de médicament par l'intermédiaire d'un lieur, un procédé pour sa préparation, une composition le comprenant et son utilisation dans le traitement d'une maladie, d'un trouble ou d'une affection.
PCT/CN2022/072296 2021-01-18 2022-01-17 Anticorps modifié et conjugués anticorps-médicament le comprenant WO2022152289A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202280010258.2A CN117255808B (zh) 2021-01-18 2022-01-17 工程化抗体和包含工程化抗体的抗体-药物偶联物
CN202410359231.5A CN118221804A (zh) 2021-01-18 2022-01-17 工程化抗体和包含工程化抗体的抗体-药物偶联物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/072424 2021-01-18
CN2021072424 2021-01-18

Publications (1)

Publication Number Publication Date
WO2022152289A1 true WO2022152289A1 (fr) 2022-07-21

Family

ID=82446970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/072296 WO2022152289A1 (fr) 2021-01-18 2022-01-17 Anticorps modifié et conjugués anticorps-médicament le comprenant

Country Status (2)

Country Link
CN (2) CN117255808B (fr)
WO (1) WO2022152289A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041543A1 (fr) * 2022-08-22 2024-02-29 Suzhou Bioreinno Biotechnology Limited Company Procédé de préparation d'un anticorps ayant des modifications spécifiques à un site de groupe thiol et utilisation de tcep
WO2024041544A1 (fr) * 2022-08-22 2024-02-29 Suzhou Bioreinno Biotechnology Limited Company Procédé de préparation d'un anticorps ayant des modifications spécifiques à un site

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110642A2 (fr) * 2010-03-10 2011-09-15 Genmab A/S Anticorps monoclonaux contre c-met
US20160067351A1 (en) * 2013-02-08 2016-03-10 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN105848671A (zh) * 2013-08-28 2016-08-10 施特姆森特克斯股份有限公司 位点特异性抗体缀合方法和组合物
WO2017205741A1 (fr) * 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
CN107530443A (zh) * 2015-03-04 2018-01-02 艾伯维施特姆森特克斯有限责任公司 工程化的位点特异性抗体和使用方法
CN111484555A (zh) * 2019-01-28 2020-08-04 正大天晴药业集团股份有限公司 新型双特异性cd3/cd20多肽复合物
US20200283524A1 (en) * 2017-09-22 2020-09-10 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
WO2021013068A1 (fr) * 2019-07-19 2021-01-28 Wuxi Biologics (Shanghai) Co., Ltd. Complexe polypeptidique pour conjugaison et son utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110642A2 (fr) * 2010-03-10 2011-09-15 Genmab A/S Anticorps monoclonaux contre c-met
US20160067351A1 (en) * 2013-02-08 2016-03-10 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
CN105848671A (zh) * 2013-08-28 2016-08-10 施特姆森特克斯股份有限公司 位点特异性抗体缀合方法和组合物
CN107530443A (zh) * 2015-03-04 2018-01-02 艾伯维施特姆森特克斯有限责任公司 工程化的位点特异性抗体和使用方法
WO2017205741A1 (fr) * 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
US20200283524A1 (en) * 2017-09-22 2020-09-10 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
CN111484555A (zh) * 2019-01-28 2020-08-04 正大天晴药业集团股份有限公司 新型双特异性cd3/cd20多肽复合物
WO2021013068A1 (fr) * 2019-07-19 2021-01-28 Wuxi Biologics (Shanghai) Co., Ltd. Complexe polypeptidique pour conjugaison et son utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCHUURMAN J, ET AL: "The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 38, no. 1, 1 January 2001 (2001-01-01), GB , pages 1 - 8, XP002329378, ISSN: 0161-5890, DOI: 10.1016/S0161-5890(01)00050-5 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024041543A1 (fr) * 2022-08-22 2024-02-29 Suzhou Bioreinno Biotechnology Limited Company Procédé de préparation d'un anticorps ayant des modifications spécifiques à un site de groupe thiol et utilisation de tcep
WO2024041544A1 (fr) * 2022-08-22 2024-02-29 Suzhou Bioreinno Biotechnology Limited Company Procédé de préparation d'un anticorps ayant des modifications spécifiques à un site

Also Published As

Publication number Publication date
CN118221804A (zh) 2024-06-21
CN117255808A (zh) 2023-12-19
CN117255808B (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
JP6770535B2 (ja) Ｃｄ１２３抗体及びその複合体
JP6714687B2 (ja) 抗体薬物複合体における共有結合リンカー、並びにその製造方法及び使用方法
CN109320612B (zh) 抗her2抗体及其缀合物
CN110240654A (zh) 结合cd73的抗体-药物偶联物
US20240050583A1 (en) Protein-drug conjugate and site-specific conjugating method
WO2022152289A1 (fr) Anticorps modifié et conjugués anticorps-médicament le comprenant
CA3058024A1 (fr) Procede de preparation de conjugue anticorps-medicament
JP6585600B2 (ja) Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法
JP7455188B2 (ja) コンジュゲーションのためのポリペプチド複合体及びその応用
CN110483639A (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
CN114829402A (zh) 抗ror1抗体及其制备方法与应用
WO2022188743A1 (fr) Conjugué anticorps-agoniste immunitaire anti-her2 et ses applications
CN113045659B (zh) 抗cd73人源化抗体
WO2022152308A1 (fr) Anticorps anti-trop2 modifié et conjugué anticorps-médicament associé
TWI845724B (zh) 用於偶聯的多肽複合物及其應用
WO2023212906A1 (fr) Anticorps comprenant une charnière modifiée et ses utilisations
CN117430708B (zh) 一种抗Claudin18.2抗体
RU2806049C9 (ru) Конъюгаты анти-her2 бипаратопных антител-лекарственных веществ и способы их применения
RU2806049C2 (ru) Конъюгаты анти-her2 бипаратопных антител-лекарственных веществ и способы их применения
KR20230066257A (ko) 리지스틴 특이적 항체 및 이의 용도
WO2021141996A1 (fr) Polypeptides à chaîne unique et à chaînes multiples qui se lient de manière spécifique à cd3 epsilon
JP2022552349A (ja) Ｂリンパ球特異的アマトキシン抗体コンジュゲート
Feng One-Bead One-Compound Combinatorial Technology as Enabling Tool for Site-Specific Derivatization of Immunoglobulins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22739164

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 202280010258.2

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22739164

Country of ref document: EP

Kind code of ref document: A1